Virginia Li's Archive

Virginia is currently a research assistant at the University of Chicago, where she studies brain development in children acquiring early language and reading skills. She recently received her B.A. in Biology from Cornell University and hopes to pursue a career in science journalism. Outside of work, she enjoys cooking, photography, and teaching gymnastics. Virginia joined The Myeloma Beacon in November 2011.

Monday was the third day of this year’s meeting of the American Society of Hematology (ASH). The day was filled with oral presentation sessions from early in the morning until into the evening.

In the afternoon and early evening, there were six oral presentation sessions devoted solely to multiple myeloma and a number of other myeloma-related presentations scattered about the afternoon. The topics of these presentations ranged from the biology of myeloma to treatment options for newly diagnosed, relapsed and …

Spanish researchers recently developed a new model based on a technique called multiparameter flow cytometry that can identify newly diagnosed multiple myeloma patients with disease profiles similar to those of patients with the myeloma precursor disease monoclonal gammopathy of undetermined significance.

The set of myeloma patients identified as having disease similar to monoclonal gammopathy of undetermined significance (MGUS) had better disease status at diagnosis and better long-term survival than other newly diagnosed myeloma patients, regardless of the depth of their …

The results of two recent European studies provide new insights into minimal residual disease detection and its potential value in the treat­ment of multiple myeloma.

The first study, carried out in Spain, used two different methods to detect mini­mal residual disease (MRD) in myeloma patients. The study found that the two methods led to similar results, and that MRD levels may be a better predictor of patient prognosis than traditional measures of treat­ment response.

This year’s annual meeting of the American Society of Clinical Oncology (ASCO) came to an end yesterday in Chicago.

Monday was the busiest day with regard to myeloma-related research. The day started with an oral presentation session that included eight talks about im­por­tant new myeloma-related research. A poster session in the afternoon included several posters about myeloma-related research.

This article summarizes the most important findings from Monday's oral pre­sen­ta­tion session. A later article will cover the findings from the after­noon …